1st Edition

Human Enhancement Drugs

ISBN 9781138552791
Published June 19, 2019 by Routledge
336 Pages

USD $150.00

Prices & shipping based on shipping country


Book Description

Despite increasing interest in the use of human enhancement drugs (HEDs), our understanding of this phenomenon and the regulatory framework used to address it has lagged behind. Encompassing public health, epidemiology, neuroethics, sport science, criminology, and sociology, this book brings together a broad spectrum of scholarly insights and research expertise from leading authorities to examine key international issues in the field of HEDs. As "traditional" and other "new" drug markets have occupied much of the academic attention, there has been a lack of scholarly focus on human enhancement drugs. This book provides readers with a much-needed understanding of the illicit drug market of HEDs. The authors, from a variety of cultural contexts, disciplines and perspectives, include both academics and practitioners. Topics explored in this collection amongst others include:

• The anti-doping industry and performance and image enhancing drugs

• Steroids and gender

• The use of cognitive enhancing drugs in academia

• The use of sunless synthetic tanning products

• The (online) trade of HEDs

• Regulations of the enhancement drugs market

This collection will serve as a reference for students, academics, practitioners, law enforcement and others working in this area to reflect on the current state of research and consider future priorities. This detailed exploration will provide a valuable knowledge base for those interested in human enhancement drugs, while also promoting critical discussion.

Table of Contents

1. An introduction to human enhancement drugs
Katinka van de Ven, Kyle J. D. Mulrooney and Jim McVeigh

Part I: Understanding the use of human enhancement drugs in society

2. More than unnatural masculinity: gendered and queer perspectives on human enhancement drugs
Kathryn (Kate) Henne and Bridget Livingstone

3. The anti-doping industry coming of age: in search of new markets
Bengt Kayser and Verner Møller

4. The social construction of human enhancement: implications for sports
Jay Coakley

5. Steroid madness: has the dark side of anabolic-androgenic steroids (AAS) been over-stated?
Kyle J. D. Mulrooney, Katinka van de Ven, Jim McVeigh and Rick Collins

6. Licit forms of performance enhancement and possible links with IPED use: current knowledge and future directions
Ian Boardley

Part II: Human enhancement drugs, harms and public health

7. Infections and risk among people who use image and performance enhancing drugs
Vivian Hope and Jenny Iversen

8. “Objects in the mirror are larger than they appear”: steroids and body image disorders
Scott Griffiths

9. Estimated prevalence, effects and potential risks of substances used for cognitive enhancement
Jamie Tully, Catharine Montgomery, Larissa J. Maier and Harry R. Sumnall

10. “Beauty through the eye of a needle”: an online study of the practices and beliefs of people who inject performance and image enhancing drugs (PIEDs)
Rebekah Brennan, John S. G. Wells and Marie Claire Van Hout

11. The use of sunless synthetic tanning products
Marie Claire Van Hout and Jim McVeigh

12. The non-medical uses of prescription stimulants in the Australian context
Matthew Dunn and Cynthia Forlini

Part III: Illicit human enhancement drug markets and their suppliers

 13. The (online) supply of illicit lifestyle medicines: a criminological study
Alexandra Hall and Georgios A. Antonopoulos

14. A preliminary attempt to scope the market for doping products in Italy
Letizia Paoli and Alessandro Donati

15. Trust, risk and deceit in the illicit medicines market: an analysis of the on- and offline trust relations between sellers and buyers of illicit medicines
Rosa Koenraadt

16. The open bar has closed: changes in the patterns of doping supply in elite cycling
Bertrand Fincoeur

17. The supply of Image and Performance Enhancing Drugs (IPED) to local non-elite users in England: resilient traditional and newly emergent methods
Ross Coomber and Mike Salinas

Part IV: Responding to human enhancement drugs

18. Different users, different interventions: on the ideal typology of anabolic-androgenic steroid use and its implications for prevention, harm reduction and treatment
Anders Schmidt Vinther and Ask Vest Christiansen

19. The war on anabolic-androgenic steroids: an examination of U.S. legislative and enforcement efforts
Rick Collins

20. Preventing image and performance enhancing drug use: it's not all chalk and talk
Geoff Bates and Susan Backhouse

21. How to respond to the increasing use of cognitive enhancers in academia?
Jason Mazanov

22. One size does not fit all: tackling the issue of weight-loss drug use
Jennifer Germain, Charlotte McLean and Conan Leavey

View More



Katinka van de Ven is a Research Fellow as part of the Drug Policy Modelling Program (DPMP) at the Social Policy Research Centre (SPRC), University of New South Wales. Katinka’s research focuses on the use and supply of performance and image enhancing drugs (PIEDs), which includes projects surrounding the prevention of PIED use, harm reduction policies and improving healthcare services for users. She is Honorary Research Fellow at the Public Health Institute, Liverpool John Moores University. Katinka is Editor-in-Chief of Performance Enhancement & Health and the Director of the Human Enhancement Drug Network (HEDN) (www.humanenhancementdrugs.com).

Kyle J. D. Mulrooney is a lecturer in Criminology at the University of New England and the co-director of the Centre for Rural Criminology (UNE). His primary field of research is the Sociology of punishment in which he has examined issues ranging from the nexus between penal populism and political culture to the areas of drug policy and rural crime. He is also particularly interested in the use, supply, and regulation of enhancement drugs. Kyle holds a PhD in Cultural and Global Criminology from the University of Kent and Universität Hamburg, an MA in the Sociology of Law from the International Institute for the Sociology of Law and a BA (Honours) in Criminology and Justice from the University of Ontario Institute of Technology.

Jim McVeigh is the Director of the Public Health Institute at Liverpool John Moores University. He has worked within health/public health for over 30 years and has built an international reputation within the field of human enhancement drug use, in particular, the use of anabolic steroids and associated drugs within the general population.